From the clinical aspect, we propose that high BCL9-2 in the primary tumor might predict a favorable therapy response to anti-estrogen treatment, based on our data analysis of tamoxifen treated patients with ER+ breast cancers [28]. The gene discussed is ESR1; the disease is breast carcinoma.